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Tuberculosis (TB) with and without associated human immunodeficiency virus (HIV) 
infection is a worldwide problem and a major concern for the world health 
organisation (WHO). In 2014 alone 9.6 million people were thought to have been 
infected with TB globally and 1.1 million HIV negative people died from TB.1 With 
migration and travel, all countries are affected with varying rates of infection with 
areas of higher rates where migrant groups settle.2 Latent TB occurs when 
individuals have been exposed to TB in the past but did not receive anti-TB 
treatment (ATT), and have remained systemically well.  
Recent migration from TB endemic countries and long duration of exposure are risk 
factors for latent TB and an associated positive QuantiFERON-TB Gold test (Qiagen, 
Chadstone, Victoria, Australia, QFT®).3 Latent TB carries a risk of about 10% of 
reactivation over a person’s lifetime although this may vary with location.4 With the 
population size involved, widespread community treatment with ATT for latent TB is 
difficult,  although in selected high risk groups it has been feasible and successful.5 A 
further important finding is that latent TB is associated with an increased risk of 
developing cancer.6 
If a patient has evidence of active TB infection, such as pulmonary signs and 
symptoms and an abnormal chest roentgenogram (CXR) with radiologic signs of 
active TB infection or clinically evident extra-pulmonary involvement, treatment is 
indicated. Uveitis associated with evidence of active infection may indicate direct 
ocular involvement by TB organisms.7-9 In other patients with severe vision 
threatening uveitis where systemic corticosteroids and steroid-sparing agents are 
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required, ATT may be indicated to prevent reactivation of latent TB, rather than to 
treat active TB related uveitis.10 
It is not uncommon when investigating patients with uveitis, that there is no 
identifiable systemic or ocular disease and that the only positive test is a 
tuberculin/QFT®.11 In such patients, the question arises as to whether the uveitis is 
related to latent TB or not and whether ATT would be beneficial. 
Recent studies in India suggest that in patients with vision threatening uveitis with no 
identifiable cause who have latent TB, the recurrence rate of the uveitis is greatly 
reduced with concomitant TB and uveitis treatment – recurrence rate 46.53% versus 
15.74% in all types of uveitis.12 Similar findings have been demonstrated by studies 
in Singapore13, the Netherlands11 and the United Kingdom.14,15 India and Singapore 
have intermediate or high population rates of TB infection and all of these studies 
included some patients with evidence of active TB on CXR in addition to patients 
with latent TB. 
 
The current study examines the clinical features and outcomes of patients presenting 
with uveitis who have no evidence of any systemic or ocular disease causing their 




This is a retrospective cohort study of patients with uveitis associated with latent TB 
attending uveitis clinics in London (UK, ethical approval for data collection 
LIGS10201) and Sydney (Australia, LNR/15/POWH/432) between the years 2007-
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2015. The patient inclusion criteria are summarised in table 1 and included a 
diagnosis of latent-TB, based on a positive tuberculin or QFT test without evidence 
of active infection or having received ATT. Children from endemic regions for TB are 
regularly screened for TB and treated as needed. In our cohort there was no 
evidence of previous testing for TB, suggesting that those who migrated from 
endemic regions, did so as adults. The presence of a Ghon focus on CXR was not 
considered evidence of active TB. We considered patients to have uveitis associated 
with latent TB if, following a complete systemic review and targeted blood 
investigations (eg toxoplasma serology, angiotensin converting enzyme, antinuclear 
antibodies, syphilis serology, complete blood count, blood electrolytes, urine 
analysis, liver enzymes and other as appropriate), there was no other identifiable 
cause for their uveitis, apart from TB. Patients were excluded if there was another 
identifiable cause for their uveitis on history, examination or investigation. The 
anatomical location of ocular involvement was based on clinical assessment at the 
time of diagnosis. A diagnosis of occlusive vasculitis was based on the presence of 
corresponding clinical findings such as vascular sheathing, retinal or vitreous 
hemorrhages and areas of capillary non-perfusion on fluorescein angiography. 
Uveitis was categorised anatomically using the SUN criteria.16 Ocular treatment was 
given, appropriate for the anatomical location of the inflammation. Patients were also 
assessed by respiratory physicians, where further investigations were performed and 
all patients were offered ATT.12 ATT consisted of four drugs: ethambutol, rifampicin, 
isoniazid and pryazinamide for two months followed by rifampicin and isoniazid only 
for a further four months, making for a total treatment time of at least six months, 
based on clinical response.17, 18 This treatment regimen was prescribed due to either 
the need for combination immunosuppressive therapy or the potential for escalation 
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of immunosuppressive treatment to treat vision threatening uveitis, both of which 
may result in reactivation of TB. Patients continued treatment with corticosteroids 
and steroid-sparing immunosuppressive drugs for their uveitis during ATT treatment. 
Additional ocular management including intraocular pressure lowering medications, 
vitrectomy for vitreous haemorrhage, argon laser photocoagulation to ischaemic 
retina causing neovascularisation, bevacizumab for secondary choroidal 
neovascularisation and cataract surgery, was instituted as needed.  
Patient demographics and clinical information including: length of follow-up, 
anatomical diagnosis of uveitis, treatment, response to treatment, duration of time to 
and number of recurrences of inflammation, ocular complications and best corrected 
visual acuity (BCVA) at presentation and final follow-up were collected. Recurrence 
of inflammation was defined as any intra-ocular inflammation occurring in the same 
eye, six or more months after uveitis was controlled. BCVA was recorded using 
Snellen charts and converted to early treatment diabetic retinopathy study (ETDRS) 
letters for statistical analysis, using conventional conversion tables.19 Patients born in 
the Indian sub-continent, Middle East, South East Asia, China, Africa or the Pacific 
islands, were considered to be from TB endemic regions.1 
 
Statistical methods 
Information from cases with bilateral ocular involvement was adjusted using 
appropriate statistical methods.20 The change in mean BCVA throughout follow-up 
was compared using generalized estimating equation, adjusting for time of follow-up 
and correlations between two treated eyes of the same patient. Multivariate analysis 
and odds ratios (OR) with 95% confidence intervals (CI) for recurrence of disease 
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was calculated using a Cox regression model while adjusting for correlations 
between both eyes of the same patient and accounting for the variable follow-up. 
Only factors with a significance level of at least 0.1 on univariate analysis were 
included in the multivariate model. In order to adjust for the increased use of ATT in 
non-AU cases, both these factors were included in the multivariate analysis. The 
Kaplan-Meier estimator was used to examine survival to the recurrence of ocular 
inflammation, and groups were compared using a log-rank test. SPSS (version 23, 
IBM, USA) was used for all analyses.  The accepted level of significance for all tests 




This study included 199 eyes of 129 patients (46.5% female) diagnosed with uveitis 
associated with latent TB (Table 2). There were no differences in the demographics 
or clinical features of the patients seen at each centre other than some small 
differences in ethnicity reflecting the different geographic locations of the two 
centres. (data not shown). The patients were therefore analysed as a single study 
population. Evidence of exposure to tuberculosis was based on a positive tuberculin 
test (induration >10 mm) (n=60) and/or a positive QFT (n=93, mean titre value- 
6.0±0.7 IU/mL). There was no difference in the positive QFT levels across the 
different clinical types of uveitis (p=0.2). Mean age at diagnosis with uveitis was 
43.9±1.3 years (range 5-77), with a median follow-up time of 29 months (range 6-
287 months). Patients in the cohort were more likely to originate from a TB endemic 
region (n=111, 86.0%). Twenty-seven patients (20.9%) had evidence of a healed 
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Ghon focus on CXR and 102 (79.1%) had a normal CXR. Non-anterior ocular 
involvement occurred in 77.9% of eyes (n=155), most commonly as occlusive 
vasculitis (n=58, 29.2%) or intermediate uveitis (n=54, 27.1%). At the time of uveitis 
diagnosis mean BCVA was 82.8±1.7 letters. Eighty-nine patients (69%) received 
ATT, of whom 87 (97.8%) suffered no serious side effects and completed a full 
course of 6 months treatment. There was no difference in the baseline 
characteristics of patients who received ATT and those who did not . Corticosteroids 
were used to treat 93.4% of eyes (69.5% topical; 15.2% periocular and 56.9% 
systemic corticosteroids), with 180 eyes (90.5%) achieving a resolution of the intra-
ocular inflammation. Patients receiving ATT were more likely to receive systemic 
corticosteroids (66.4% vs. 33.3%, p<0.001). Throughout follow-up, second-line 
immunosuppressive agents were given to treat 10 patients (18 eyes), in four eyes 
prior to or at the time ATT was started. Patients receiving ATT were not more likely 
to be treated with second-line immunosuppression (9.3% vs. 2.6%, p=0.27). Ocular 
complications, following uveitis diagnosis, developed in 71 eyes (35.7%), most 
commonly cystoid macular edema (n=19, 9.5%) and cataract (n=18, 9%). 
Over the period of follow-up, the mean change in BCVA following treatment was 
4.5±1.4 letters. There was no difference in the mean change in BCVA between eyes 
of patients treated with ATT and those who were not (5.3±1.5 vs. 3±3.1 letters 
respectively, p=0.16), nor between those treated with systemic corticosteroids and 
those who were not (6.73±1.8 vs. 2±2.1 letters, respectively, p=0.27). Among eyes 
with moderate vision loss (MVL, 20/200<BCVA <20/40, n=96) or severe vision loss 
(SVL, BCVA ≤20/200, n=44) at diagnosis, treatment with systemic corticosteroids 
resulted in a significant improvement in BCVA in both patients with MVL (8.9±3.5, 
p<0.001) and SVL (22.9±6.5, p<0.001). No effect on final BCVA occurred with ATT. 
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The proportion of eyes that gained 15 letters was the same in those treated with ATT 
(22%) and those that did not receive ATT (19%, OR 0.97 95% CI 0.47-2.0, p=0.9). 
There no difference in the proportion of eyes that gained 15 letters between those 
treated with systemic corticosteroids and those that were not (27.7% vs. 12.9%, OR 
1.34 95% CI 0.66-2.72, p=0.4). There was also no relation between treatment with 
either ATT or corticosteroids and the chance of avoiding severe vision loss, defined 
as loss of 15 letters or more. 
During follow-up all patients were able to stop uveitis treatment, but 68 eyes (34.9%) 
had a recurrence of ocular involvement with a mean of 2.3±0.36 recurrences 
(0.64±0.08 recurrences per-year). The risk factors for disease recurrence were 
identified using multivariate analysis (Table 3). Eyes of patients receiving ATT were 
half as likely to develop a recurrence as those not receiving ATT (29.5% vs. 48.2%, 
OR 0.5, 95% CI 0.31-0.83, p=0.006). When examined as a single factor, eyes with 
non-AU disease were less likely to develop disease recurrence. However, once 
adjusting for other factors, including use of ATT it was not significant on multivariate 
analysis. There was no increased risk of recurrence among patients from TB 
endemic regions (35.7% vs. 29.6%, OR 1.27, 95% CI 0.61-2.66, p=0.53), between 
eyes treated with or without systemic corticosteroids (35.2% vs. 35.3%, OR 0.78, 
95% CI 0.48-1.27, p=0.32) or between eyes treated with or without second-line 
immunosuppression agents (27.8% vs. 35.7%, OR 0.44, 95% CI 0.62-3.88, p=0.34). 
Estimated median time to first recurrence was 79 months (95% CI 45.7-112.3), with 
eyes treated with ATT recurring at an estimated median of 120 months compared 
with 51 months in eyes not treated with ATT (95% CI 20.2-81.8, p=0.005, Figure 1A). 
Eyes with non-AU had a median time to first recurrence of 79 months (95% CI 0-
160.0), significantly longer than eyes with AU that had an estimated median time of 
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56 months (95% CI 24.0-88.0, p=0.03, Figure 1B). There was no difference between 
eyes treated with systemic corticosteroids and those that were not. 
 
Discussion 
This study characterises and provides evidence of the outcome of uveitis associated 
with latent TB, and the role of ATT in preventing disease recurrence. Following 
diagnosis and treatment visual function remained stable throughout follow-up and 
patients maintained visual acuity. Treatment with ATT halved the risk of recurrence 
and delayed the onset of the first recurrence. 
 
 
The clinical features of the uveitis in this study reflect patterns of uveitis previously 
recognised as commonly occurring in patients with proven or suspected TB related 
uveitis. In this study, occlusive retinal vasculitis was the most frequent pattern of 
uveitis. Occlusive retinal vasculitis has been recognised for more than a century as 
an important vision threatening ocular association of TB and is frequently called 
Eales disease.21,22 Eales’ original disorder is now considered part of a spectrum of 
occlusive retinal vasculitis associated with variable inflammatory signs in the vitreous 
and anterior chamber, retinal neovascularisation and vitreous haemorrhage.23,24 It 
can be a severe vision threatening form of uveitis requiring aggressive systemic 
immunosuppressive therapy and ablative retinal photocoagulation to ischaemic 




All anatomical types of uveitis have been reported in patients with latent TB, with 
intermediate uveitis, AU and multifocal choroiditis common in our study population. 
Patients were managed using local and/or systemic therapy based on the presence 
of an inflammatory mediated threat to vision such as macular oedema with 
decreased vision. Serpiginous choroidopathy was the least common pattern of 
uveitis. It is recognised that in up to 20% of patients diagnosed with serpiginous 
choroidopathy, especially those with atypical clinical features or in patients from TB 
endemic regions, the uveitis is TB related and requires ATT in addition to 
immunosuppressive therapy.25,26 Patients in this study were more likely to originate 
from endemic regions.  
Where immunosuppressive agents are not required to treat the uveitis, the question 
arises as to whether to treat the latent TB infection on the grounds that it may be 
driving the uveitis,27 raising the problems related to ATT compliance, drug toxicities 
and patient unwillingness to take medication for at least six months. There is no 
consensus on whether ATT in patients with uveitis and latent TB should be given for 
six, nine months or even longer. In this study, all patients were offered ATT because 
of the potential escalation of immunosuppressive treatment, which would then 
require addressing their TB status. AU recurred significantly more frequently and at a 
shorter latency than the other types of uveitis. This may reflect a higher risk of 
disease recurrence for AU or the more chronic nature of non-AU disease.   
In some patients there is direct invasion by TB mycobacteria as evidenced by the 
positive culture or histopathological identification of organisms from involved ocular 
tissue. In other patients such as those included in the current study, there is no 
clinical evidence to suggest active TB infection. The pathogenesis of uveitis in these 
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patients remains unclear and it is uncertain whether the uveitis is a hypersensitivity 
response to TB organisms (either local or remote from the eye) or the result of 
reactivation of latent ocular infection by M. tuberculosis. It is theorised that bacteria-
laden macrophages from alveoli may enter the lymphatics and circulation carrying 
bacteria to the eye, where the organisms may persist and initiate an immune-
mediated response.21, 28 The association between TB and retinal vasculitis, 
serpiginous choroiditis, and other clinical presentations has been supported by the 
identification of M. tuberculosis DNA by polymerase chain reaction (PCR).28-31  
The current study provides significant further evidence implicating localised ocular 
reactivation of mycobacteria as the likely mechanism of TB related uveitis. In this 
study, there was no clinical evidence supporting a hypersensitivity response in any 
tissue outside the eye such as skin rash, erythema nodosum or peripheral 
neuropathy. There was a dramatic reduction in the recurrence rate of uveitis and a 
significant delay in time to uveitis recurrence, following treatment with ATT. 
Additionally, there is ample precedent for similar isolated intraocular reactivation of 
infection without reactivation of systemic infection, in patients with ocular 
toxoplasmosis and ocular herpetic infection. 
The results of this study from a distinct cohort of patients, with evidence of TB 
exposure and a limited spectrum of uveitis clinical phenotypes, suggest there is a 
significant role for TB in the ocular disease. The study provides important treatment 
outcome data that informs clinicians managing patients similar to those in this study. 
The critical findings are that treatment with ATT was well tolerated, reduced the 
frequency of uveitis recurrence by 50% and significantly increased the time to 
recurrence. These findings have been reported in earlier studies, earlier studies have 
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comprised a mixed population of patients with both latent and active TB.12-15 The 
current study is the first to demonstrate the positive effects of ATT in a series of 
patients with latent TB. In non-TB endemic regions such patients are by far the most 
common group of patients with TB related uveitis. Treatment for latent TB did not 
alter the visual outcome and importantly was not associated with any increased risk 
of severe vision loss. While treatment with ATT is not without systemic side effects, 
resulting in poor patient compliance in many cases, this positive effect should be 
considered when considering treatment in patients with uvieits associated with latent 
TB. The other important finding in this study is that treatment with oral corticosteroids 
also did not reduce the proportion of patients gaining vision nor did it increase the 
likelihood of severe vision loss. Among those with a loss of vision, corticosteroids 
had a positive effect, with significant visual improvement, suggesting a ceiling effect 
among those with good vision at diagnosis. Steroid therapy did not increase either 
the risk of recurrence or the time to recurrence of uveitis. 
 
The strength of the study is the large uniform patient cohort with uveitis associated 
with latent TB. The study is limited by the retrospective collection of data, the 
variable length of follow-up and missing patient information. There was a high 
proportion of patients with good initial visual acuity limiting the ability for the study to 
demonstrate significant improvement in visual acuity. There is recruitment bias as 
patient inclusion, patient exclusion and treatment were managed by a number of 
ophthalmologists and TB physicians. It is possible that with longer follow-up more 
patients might have disease recurrence, which would reduce the difference in rate of 
recurrence and time to recurrence. With a median follow-up of two and a half years, 
the results of this study provide useful medium-term outcome data.  
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Overall, the results of this study provide strong, positive evidence of the benefit of 
treating patients with uveitis associated with latent TB with ATT in addition to 
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Figure 1- Survival to first recurrence of TB related uveitis. (A) in eyes receiving ATT 
median time to recurrence was 120 months compared with 26 months in eyes with 
no treatment (95% CI 2.7-49.3, p=0.002). (B) Eyes with non-AU had a median time 
to first recurrence of 79 months (95% CI 13.1-144.91) compared with 42 months in 
eyes with AU (95% CI 13.87-70.13, p=0.004). 
